Gilead Sciences 3Q Results Beat Estimates
November 07 2023 - 3:51PM
Dow Jones News
By Denny Jacob
Gilead Sciences posted better-than-expected top- and bottom-line
results in the latest quarter, which the company credited to its
virology and oncology segments.
The biopharmaceutical company logged net income of $2.18
billion, or $1.73 a share, for the third quarter ended Sept. 30,
compared to $1.79 billion, or $1.42 a share, a year earlier.
Adjusted earnings were $2.29 a share, above analysts' estimates of
$1.92 a share.
Revenue edged up slightly to $7.05 billion from $7.04 billion a
year earlier. Analysts polled by FactSet expected $6.81
billion.
Gilead said revenue was flat as increased sales in oncology and
HIV were offset by lower Veklury and chronic hepatitis C virus
product sales.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 07, 2023 16:36 ET (21:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024
